NCT05228470 2026-01-06
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
Phase 2 Completed
Pfizer
University of Minnesota
Oregon Health and Science University
National Center for Complementary and Integrative Health (NCCIH)